Nika Pharmaceuticals, Inc's Form 4 filing
Nika Pharmaceuticals, Inc (NIKA) · filed Mar 19, 2024
- Accession no.
- 0001826466-24-000034
- Filed
- Mar 19, 2024, 2:08 PM ET
- Trade date
- Apr 13, 2022-Jun 2, 2023
- Filing delay
- 706 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions. Open-market purchases total $137.9K. Open-market sales total $410.0K. It was filed 706 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nika Pharmaceuticals, IncCIK 0001145604 | Director, Officer (President, CEO, CFO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 13, 2022 | Preferred A Stock | JOtherAcquired | +10,000,000 | $3,000,000.00F2 | +$30,000,000,000,000 | 10,000,000 | Direct | Price outlier |
| Apr 13, 2022 | Common | PPurchaseAcquired | +11,489,000 | $0.012 | +$137,868 | – | Direct | |
| Jul 20, 2022 | Common | JOtherAcquired | +333,181,000 | $0.00 | $0 | – | Direct | |
| Sep 12, 2022 | Common | SSaleDisposed | −7,000,000 | $0.02 | −$140,000 | – | Direct | |
| Sep 26, 2022 | Common | SSaleDisposed | −1,250,000 | $0.02 | −$25,000 | – | Direct | |
| Oct 24, 2022 | Common | SSaleDisposed | −3,000,000 | $0.037 | −$111,000 | – | Direct | |
| Jan 10, 2023 | Common | SSaleDisposed | −6,300,000 | $0.01 | −$63,000 | – | Direct | |
| Jan 31, 2023 | Common | SSaleDisposed | −1,500,000 | $0.01 | −$15,000 | – | Direct | |
| Jun 2, 2023 | Common | SSaleDisposed | −3,500,000 | $0.016 | −$56,000 | – | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Exclusive rights valued at 3,000,000
Referenced by the price of 1 transaction in Table I.